Regulus Therapeutics Inc (RGLS) オプション

RGLS..................................https://stockcharts.com/h-sc/ui?s=RGLS&p=W&b=5&g=0&id=p86431144783

RGLS.................................................https://stockcharts.com/h-sc/ui?s=RGLS&p=W&b=5&g=0&id=p86431144783

RGLS8429: Phase 1b MAD study ongoing
• Presented topline data in September 2023 from the first cohort of patients in the
Phase 1b MAD study indicating increases in both PC1 and PC2 urine biomarkers after
treatment
• In March 2024, presented topline data from the second cohort:
• Greater biological activity of RGLS8429 was observed at 2 mg/kg based on urinary polycystin levels
compared to 1 mg/kg and placebo
• The largest reductions in htTKV were seen in patients with the highest increase in PC1 and PC2
• Completed enrollment in the third cohort and top-line data anticipated mid-2024
• Initiated enrollment in the fourth and final cohort

Kiwi

RGLS................................https://stockcharts.com/h-sc/ui?s=RGLS&p=W&b=5&g=0&id=p86431144783

FWIW Jones Trading analyst Catherine Novack initiates coverage on Regulus Therapeutics ( RGLS ) with a Buy rating and announces Price Target of $8.

Kiwi

FWIW Jones Trading analyst Catherine Novack initiates coverage on Regulus Therapeutics ( RGLS ) with a Buy rating and announces Price Target of $8.

Kiwi

Regulus is currently dosing patients in the third cohort of the MAD study patients with either 3mg/kg of RGLS8429 or a placebo every other week for three months. Enrolment in this cohort has been completed and top-line data from the same is expected in mid-2024.

That was March 13th .......So by June 13th the 3 mth dosing is over ...small number so data a week or 2 later ??
Kiwi

RGLS. Getting some interest today ...not sure what the catalyst is ...impending data ?
Kiwi

Well they had positive topline data in March for cohort 2 and expect cohort 3 data by July or so. Higher dosage in cohort 3. 3mg per kg. Also starting cohort 4. Will keep an eye on this. No position yet.

RGLS . I have a small position in this Co
Reasons for my position ?
Theres currently only 1 med available specific to ADPKD kidney disease and its poorly tolerated ( makes you pee a lot ) and not very effective.
There are around 160,000 ADPKD patients in the US and around 55% of them will have kidney failure and need dialysis by age 55.
My wife rounds dialysis clinics and writes reports on roughly 120 dialysis patients each month ..There is a high mortality rate for dialysis patients ...you can google or perplexity the numbers if you wish.
RGLS 's med slows the formation of cysts in the kidney filtration system and so far appears very safe and well tolerated.
This is P 1 data . P2 trials expected in 2025 will an expected application for accelerated approval .
So early days
Vivo Capital owns roughly 8% of the outstanding shares ( IIRC ) . Vivo specializes in a lot of niche kidney specific drugs in development ...UNCY for example
Kiwi

RGLS under $3

RGLS........................https://stockcharts.com/h-sc/ui?s=RGLS&p=W&b=5&g=0&id=p86431144783

$RGLS in with 15,000 shares!! See ya at $9 share shortly!!

BLASTOFF ROCKETSHIP IMMINENT!!

Respectfully,
Maverick

$RGLS
RGLS

Multi day runner

RGLS new 52 week hi

RNAZ Is next Cancer breakthrough this week

Wild

Halt

A lot of bids popped up

Riding the waves chippy surf today

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

Still good here

I took a much larger position after RGLS crashed after stopping trials on it first drug candidate in favor of the one they are pursuing now. Did you know Regulus was started by a collaboration of two BPs and the scientists of Regulus came from the research divisions of those BPs?

Hi Jimmy, yes I agree. Investors starting to flock here.Looking sweet!

very strong clinical science

Very strong today!

Not good news Friday after 4PM. Still PPS not down that much. Will it drift lower next week.

RGLS

Interesting, PPS didn't drop after R/S. Trading in same range.

RGLS

Interesting, PPS didn't drop after R/S. Trading in same range.

RGLS

R/S 10 = 1. less than expected. A/S reduced from 400mil to 300mil.. Watch.

RGLS

News: Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SAN DIEGO, June 21, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).


"Patients living with ADPKD currently have limited treatment options and approximately half of patients develop end-stage renal disease by age 60 requiring dialysis or transplantation," commented Jay Hagan, CEO of Regulus Therapeutics. "ADPKD is a disease of high unmet need affecting nearly 160,000 Americans. We look forward to advancing RGLS8429 through the clinic with the goal of improving future treatment options for patients in need."

The FDA's Office of Orphan Products Development grants orphan designation status to drugs and biologics that are intended for the safe and effective treatment, diagnosis or prevention of rare diseases, or conditions that affect fewer than 200,000 people in the U.S. Orphan designation status is intended to facilitate drug development for rare diseases and may provide several benefits to drug developers, including financial incentives, to support clinical development and the potential for up to seven years of market exclusivity in the U.S. upon regulatory approval.

About ADPKD
Autosomal Dominant Polycystic Kidney Disease (ADPKD), caused by mutations in the PKD1 or PKD2 genes, is among the most common human monogenic disorders and a leading cause of end-stage renal disease. The disease is characterized by the development of multiple fluid filled cysts primarily in the kidneys, and to a lesser extent in the liver and other organs. Excessive kidney cyst cell proliferation, a central pathological feature, ultimately leads to end-stage renal disease in approximately 50% of ADPKD patients by age 60. Approximately 160,000 individuals are diagnosed with the disease in the United States alone, with an estimated global prevalence of 4 to 7 million.

About RGLS8429
RGLS8429 is a novel, next generation oligonucleotide for the treatment of ADPKD designed to inhibit miR-17 and to preferentially target the kidney. Administration of RGLS8429 has shown robust data in preclinical models, where clear improvements in kidney function, size, and other measures of disease severity have been demonstrated along with a superior pharmacologic profile in preclinical studies compared to Regulus' first-generation compound. Regulus is currently conducting a Phase 1 single-ascending dose study in healthy volunteers to assess safety, tolerability, and pharmacokinetics of RGLS8429.

About Regulus

Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. Regulus maintains its corporate headquarters in San Diego, CA.

Forward-Looking Statements

Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the Company's RGLS8429 program, including the potential outcome of clinical development. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and in the endeavor of building a business around such drugs, and the risk additional toxicology data may be negative. In addition, while Regulus expects the COVID-19 pandemic to adversely affect its business operations and financial results, the extent of the impact on Regulus' ability to achieve its preclinical and clinical development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission, including under the "Risk Factors" heading of Regulus most recently quarterly report on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

View original content to download multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-receipt-of-fda-orphan-drug-designation-for-rgls8429-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-301571856.html

SOURCE Regulus Therapeutics Inc.

Copyright 2022 PR Newswire

Good news on FDA orphan drug,

RGLS

About to pop

Another nice move.

RGLS

Lol! I'm not in, never been, but I'm hopeful that no one took the bait on this "news" release. I hope everyone does great here, but I won't be one of them.

Anything these days for this company IMO was news. I would’ve taken the company newsletter of reporting a flat tire in the parking lot as news at this point. Lol

#DDAmanda Chart on: $RGLS :

You can scan for these before they run.
Contact/Text: 760 702-2009



What the Fact (Factor) Column is:

The Factor is a proprietary indicator used for scanning in #DDAmanda.

It's defined as Today's $Traded divided by the average daily $Traded (20 day avg).

SO, if a stock has say a 10 Factor that day, it means she traded 10 Times the $ she normally trades.

That's significant, and many times indicates that a run in the stock is coming.







Z

UP 80% on this little news. Holding some ...trading some.

RGLS

It's not even news. They "accepted" the application. I could go to Burger King right now and they'd "accept" my application!!

Finally a little good news!!!! Let’s go!!!!!

$pop$... 50%

RGLS

Nice news.

RGLS

Bid for new low..

RGLS

Premarket large bid. No sales. Buyout rumor?

RGLS

And now enrollments are completed for the Alport syndrome trial.

Interesting after hours buys on news.

https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-successful-completion-of-pre-ind-meeting-with-fda-for-rgls8429-301465408.html


RGLS

Good job. Wait a year or two.. They just are using knowledge learned from 1st candidate with 2nd better candidate. Could be 10 bagger in 2-3 years. I have time to Wait. Well managed and this is a BP supported roll out type company like MRUS.

Put in lowish bid after your post. Filled and green already. Think I can flip and pocket 25 cents!!

RGLS

WTF? Selling shareholders had 96 million shares of I assume warrants and option so now they can dump for .28 or is it because they are registered so they can be sold in a buyout or after some horizon event? I do not have a clue what is happening with the big dump in price other than that selling sharehold DEC registration. They do not dilute further because they were already out there. Not newly issued shares and not sold yet so wondering what is up with the 7% slide in SP.

Regulus checks all the boxes for patient long term pre-revenue biotech growth/value investors. It also looks like a timely time to buy. A year out from catalysts and more than two years cash runway. Buy low and just wait for the forest to grow.